The Cancer Researcher
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
The Cancer Researcher
No Result
View All Result

News Summary: CancerSEEK blood test, immune system vs. CRISPR

July 17, 2018
News Summary: CancerSEEK blood test, immune system vs. CRISPR

Credit: Illustration by Elizabeth Cook & Kaitlin Lindsay

CancerSEEK blood test detects 8 common cancers

A team of researchers from Johns Hopkins University have trialled a blood test, CancerSEEK, that could identify non-metastastic cancers in the ovary, liver, esophagus, pancreas, stomach, colorectal, lung, and breast.

The CancerSEEK test looks for mutations in 16 genes that regularly arise in cancer and eight proteins that are often released. It could allow for earlier detection of cancers as well as being non-invasive and low-cost.

The test was trialled on over 1000 patients already diagnosed with non-metastatic cancers, and detected cancer with a sensitivity of 69 to 98% (depending on cancer type). The results have been published in the journal Science. View the abstract here.

EACR Past President Professor Richard Marais was interviewed by the BBC about the significance of the development. Watch a short clip here.


The immune system could thwart some CRISPR gene therapies

The body’s own immune system could thwart some efforts to develop gene therapies based on the trendy genome-editing tool called CRISPR-Cas9, according to a study released on 5 January.

The study is a Preprint at bioRxiv: Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans

Click here to read an in-depth Nature News article explaining the process


Thermo Fisher Scientific and Illumina sign agreement to provide research market broader access to Ion AmpliSeq technology

Thermo Fisher Scientific and Illumina, Inc. have signed a commercial agreement that enables Illumina to sell Thermo Fisher’s  Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing platforms. Ion AmpliSeq technology is used to capture DNA and RNA from minute amounts of samples for application in multiple areas of research.

The agreement enables Illumina customers to utilize targeted resequencing as a follow-up to larger-scale exome and whole genome discovery studies.

Read the full announcement on Business Wire


 

Tags: CancerSEEKCRISPRnews summary

Related Posts

Recipients announced for the 2026 EACR-Worldwide Cancer Research Collaboration Fellowships

Recipients announced for the 2026 EACR-Worldwide Cancer Research Collaboration Fellowships

October 21, 2026

The European Association for Cancer Research and Worldwide Cancer Research are happy to announce the recipients of the 2026 EACR-Worldwide Cancer Research Collaboration Fellowships. The Collaboration...

VIDEO | Transcriptome and repertoire profiling of infiltrating γδ T cells to decode tumor escape at single cell resolution

VIDEO | Transcriptome and repertoire profiling of infiltrating γδ T cells to decode tumor escape at single cell resolution

October 22, 2026

Click above to watch "It was very informative, the speakers were brilliant and easy to follow" – feedback from a participant On 07 October 2026, the...

VIDEO | The Evolving ADC Landscape: From Monotherapies to Rational Combinations and Next-Generation Platforms

VIDEO | The Evolving ADC Landscape: From Monotherapies to Rational Combinations and Next-Generation Platforms

October 22, 2026

Click above to watch "High-quality, relevant content with clear insights from industry experts, useful for my translational cancer research." – feedback from a participant On 29...

The Cancer Researcher EACR logo

About Us

The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.

The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”

Advertisement Advertisement Advertisement
ADVERTISEMENT

RECENT POSTS

Recipients announced for the 2026 EACR-Worldwide Cancer Research Collaboration Fellowships
Community

Recipients announced for the 2026 EACR-Worldwide Cancer Research Collaboration Fellowships

October 21, 2026
Magdalena Sznurkowska’s EACR-AstraZeneca Postdoctoral Fellowship – Final Report
Career

Magdalena Sznurkowska’s EACR-AstraZeneca Postdoctoral Fellowship – Final Report

October 12, 2026
The Cancer Researcher

© 2025 EACR

Navigate site

  • About
  • Privacy
  • Main EACR website

Follow us

No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious

© 2025 EACR